Protox has positive six-month Phase 2b BPH results

Protox Therapeutics (TSX:PRX) has released positive six-month data from its Phase 2b TRIUMP study of its PRX302 drug in patients with moderate-to-severe benign prostatic hyperplasia. The study met its primary endpoint with a statistically significant improvement in International Prostate Symptom Score at day-90 for patients treated with PRX302 versus placebo and requires additional patient assessments [...]